Global Health and Lincoln Park team up
This article was originally published in The Tan Sheet
Executive Summary
Specialty pharmaceutical firm Global Health Ventures signs an equity purchase agreement with Lincoln Park Capital Fund for up to $20 million, the Canadian maker of sublingually delivered lifestyle products said May 28. Global Health says it has the right to sell shares of common stock to the Chicago-based institutional investor over a 30-month period in amounts between $100,000 and $1 million, and up to the $20 million limit depending on conditions of the agreement. Global Health says the finance proceeds will help it develop the male enhancement drug X-Excite and other drugs, license new products and acquire other companies